Results

Syndax Pharmaceuticals Inc.

09/27/2021 | Press release | Distributed by Public on 09/27/2021 04:09

The two companies expect to expand development of axatilimab in chronic graft-versus-host disease (cGVHD) with additional monotherapy and combination trials planned in 2022[...]